Prognostic and diagnostic significance of serum p53 antibody levels in patients with surgically treated pancreatic cancer
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Serum p53 antibody (s-p53-Ab) levels increase in patients with various cancer types; however, their clinicopathological relevance in pancreatic ductal adenocarcinoma (PDAC) is not well defined. The present study aimed to assess the prognostic value of s-p53-Ab status in PDAC. The present retrospective study included 124 patients who underwent surgery for PDAC between January 2012 and December 2023. Patients were categorized into s-p53-Ab(+) and s-p53-Ab(-) groups using a cutoff value of 1.3 U/ml. Prognostic significance was examined using univariate and multivariate analyses. A total of 25 patients (20%) were s-p53-Ab-positive. The isolated s-p53-Ab positivity rates in stage I and II disease were 10 and 8%, respectively. The s-p53-Ab(+) group exhibited significantly worse overall survival (P=0.038) and relapse-free survival (P=0.037) than the s-p53-Ab(-) group. Multivariate analysis revealed that s-p53-Ab(+) independently predicted poorer relapse-free survival (P=0.044) and overall survival (P=0.048). s-p53-Ab was occasionally positive in stage I/II PDAC and was associated with more aggressive disease behavior. The present study was registered as a clinical trial in the University Hospital Medical Information Network Clinical Trials Registry (registration number, UMIN000014530; date of registration, 2011/07/11).
Fields of Study & Subjects
Pancreatic and Hepatic Oncology Research
Cholangiocarcinoma and Gallbladder Cancer Studies
Breast Cancer Treatment Studies
Publication details
- Journal / source
- Oncology Letters
- Volume
- 31
- Issue
- 5
- Pages
- 1–8
- Publication date
- 30 March 2026
- Language
- EN